Endocrinology, Vol 137, 1698-1705, Copyright © 1996 by Endocrine Society

ARTICLES

Prostaglandin E receptor subtypes in mouse osteoblastic cell line

M Suda, K Tanaka, K Natsui, T Usui, I Tanaka, M Fukushima, C Shigeno, J Konishi, S Narumiya, A Ichikawa and N Nakao
Department of Medicine, Kyoto University Graduate School of Medicine, Japan.

PGE2 is one of the key molecules in the osteoblast. It is the major prostanoid in the bone, and its production is under the control of both systemic and local factors. PGE2 has been reported to have multiple actions in the osteoblast, such as growth promotion and cell differentiation. To better understand the action of PGE2 in the osteoblast, we determined the PGE receptor subtypes in MC3T3-E1, an osteoblastic cell line derived from the normal mouse calvaria. Northern blot analysis revealed that EP1 and EP4 subtypes are expressed in MC3T3- E1. In contrast, EP3 subtype was not detected by either Northern blot analysis or RT-PCR. The contribution of each subtype was evaluated by studying the effects of subtype-specific analogs on osteoblastic function at confluency and 5 days after confluency. An EP1 agonist, 17- phenyl-omega-trinor PGE2, increased DNA synthesis and decreased alkaline phosphatase activity. 11-Deoxy-PGE1, and EP2 and EP4 agonist, decreased DNA synthesis and increased alkaline phosphatase activity at both stages. Butaprost, an EP2-selective agonist, showed effects similar to those of 11-deoxy-PGE1 only at confluency. Another and more differentiated osteoblastic marker, osteocalcin production, was detectable and was stimulated by 11-deoxy-PGE1 only 5 days after confluency. The exposure of these cells to EP1 agonist changed the cell shape to a more fibroblastic appearance. These results indicate that EP1, EP4, and probably EP2 are present in MC3T3-E1 cells; EP1 promotes cell growth, and EP2 and EP4 mediate differentiation of the osteoblast. Furthermore, the decreased response to EP2-specific agonist 5 days after confluency suggests that the expression of PGE receptor subtype is dependent on the stage of osteoblastic differentiation. This is the first report to determine PGE receptor subtypes in the bone.

This article has been cited by other articles:

				J. Y. Wu, L. E. Purton, S. J. Rodda, M. Chen, L. S. Weinstein, A. P. McMahon, D. T. Scadden, and H. M. Kronenberg Osteoblastic regulation of B lymphopoiesis is mediated by Gs{alpha}-dependent signaling pathways PNAS, November 4, 2008; 105(44): 16976 - 16981. [Abstract] [Full Text] [PDF]

				T. Nomura, H. Y. Chang, R. Lu, J. Hankin, R. C. Murphy, and V. L. Schuster Prostaglandin Signaling in the Renal Collecting Duct: RELEASE, REUPTAKE, AND OXIDATION IN THE SAME CELL J. Biol. Chem., August 5, 2005; 280(31): 28424 - 28429. [Abstract] [Full Text] [PDF]

				C.-H. Tang, R.-S. Yang, and W.-M. Fu Prostaglandin E2 Stimulates Fibronectin Expression through EP1 Receptor, Phospholipase C, Protein Kinase C{alpha}, and c-Src Pathway in Primary Cultured Rat Osteoblasts J. Biol. Chem., June 17, 2005; 280(24): 22907 - 22916. [Abstract] [Full Text] [PDF]

				A. Sakamoto, M. Chen, T. Nakamura, T. Xie, G. Karsenty, and L. S. Weinstein Deficiency of the G-protein {alpha}-Subunit Gs{alpha} in Osteoblasts Leads to Differential Effects on Trabecular and Cortical Bone J. Biol. Chem., June 3, 2005; 280(22): 21369 - 21375. [Abstract] [Full Text] [PDF]

				F. Okamoto, H. Kajiya, H. Fukushima, E. Jimi, and K. Okabe Prostaglandin E2 activates outwardly rectifying Cl- channels via a cAMP-dependent pathway and reduces cell motility in rat osteoclasts Am J Physiol Cell Physiol, July 1, 2004; 287(1): C114 - C124. [Abstract] [Full Text] [PDF]

				H. Samoto, E. Shimizu, Y. Matsuda-Honjyo, R. Saito, S. Nakao, M. Yamazaki, S. Furuyama, H. Sugiya, J. Sodek, and Y. Ogata Prostaglandin E2 Stimulates Bone Sialoprotein (BSP) Expression through cAMP and Fibroblast Growth Factor 2 Response Elements in the Proximal Promoter of the Rat BSP Gene J. Biol. Chem., August 1, 2003; 278(31): 28659 - 28667. [Abstract] [Full Text] [PDF]

				J. Theilhaber, T. Connolly, S. Roman-Roman, S. Bushnell, A. Jackson, K. Call, T. Garcia, and R. Baron Finding Genes in the C2C12 Osteogenic Pathway by k-Nearest-Neighbor Classification of Expression Data Genome Res., January 1, 2002; 12(1): 165 - 176. [Abstract] [Full Text] [PDF]

				M. Machwate, S. Harada, C. T. Leu, G. Seedor, M. Labelle, M. Gallant, S. Hutchins, N. Lachance, N. Sawyer, D. Slipetz, et al. Prostaglandin Receptor EP4 Mediates the Bone Anabolic Effects of PGE2 Mol. Pharmacol., July 1, 2001; 60(1): 36 - 41. [Abstract] [Full Text]

				X. Li, Y. Okada, C. C. Pilbeam, J. A. Lorenzo, C. R. J. Kennedy, R. M. Breyer, and L. G. Raisz Knockout of the Murine Prostaglandin EP2 Receptor Impairs Osteoclastogenesis in Vitro Endocrinology, June 1, 2000; 141(6): 2054 - 2061. [Abstract] [Full Text] [PDF]

				T. Suzawa, C. Miyaura, M. Inada, T. Maruyama, Y. Sugimoto, F. Ushikubi, A. Ichikawa, S. Narumiya, and T. Suda The Role of Prostaglandin E Receptor Subtypes (EP1, EP2, EP3, and EP4) in Bone Resorption: An Analysis Using Specific Agonists for the Respective EPs Endocrinology, April 1, 2000; 141(4): 1554 - 1559. [Abstract] [Full Text] [PDF]

				S. Narumiya, Y. Sugimoto, and F. Ushikubi Prostanoid Receptors: Structures, Properties, and Functions Physiol Rev, October 1, 1999; 79(4): 1193 - 1226. [Abstract] [Full Text] [PDF]

				C. Miyaura, M. Inada, T. Suzawa, Y. Sugimoto, F. Ushikubi, A. Ichikawa, S. Narumiya, and T. Suda Impaired Bone Resorption to Prostaglandin E2 in Prostaglandin E Receptor EP4-knockout Mice J. Biol. Chem., June 23, 2000; 275(26): 19819 - 19823. [Abstract] [Full Text] [PDF]

				M. D. Southall and M. R. Vasko Prostaglandin Receptor Subtypes, EP3C and EP4, Mediate the Prostaglandin E2-induced cAMP Production and Sensitization of Sensory Neurons J. Biol. Chem., May 4, 2001; 276(19): 16083 - 16091. [Abstract] [Full Text] [PDF]